Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06664853 · ClinicalTrials.gov registry record · Phase 3
Open-Label Extension of EryDex Study IEDAT-04-2022
A Phase 3 study, sponsored by Quince Therapeutics S.p.A..
- Terminated
- Registry status
- Phase 3
- Development phase
- 101
- Enrollment target
NCT06664853: Clinical Trial Phase 3 study, sponsored by Quince Therapeutics S.p.A..
NCT06664853 is a Phase 3 study that was terminated before completion, run by Quince Therapeutics S.p.A.. The registered enrollment target is 101 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06664853, a Phase 3 study, was terminated before completion, sponsored by Quince Therapeutics S.p.A..
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 101 participants
- Enrollment target
Study Summary
This is an international, multi-center, prospective, open-label, non-comparative study aiming to provide access to treatment with EryDex to ataxia telangiectasia (A-T) patients who completed the IEDAT-04-2022 trial which studied the neurological effects of EryDex on subjects with ataxia telangiectasia (NEAT trial).
Primary Outcome
Number of participants presenting at least one treatment emergent adverse event (TEAE)
Interventions
- DRUG Dexamethasone sodium phosphate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2024-12-11 |
| Est. Completion | 2026-01-30 |
| Phase | Phase 3 |
Why NCT06664853 stopped before completion
NCT06664853 is an interventional study that assigns participants to a tested intervention. The registered 101 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 1 intervention - of which Dexamethasone sodium phosphate is the first listed.
NCT06664853 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06664853 about?
NCT06664853 is a clinical study titled "Open-Label Extension of EryDex Study IEDAT-04-2022". This is an international, multi-center, prospective, open-label, non-comparative study aiming to provide access to treatment with EryDex to ataxia telangiectasia (A-T) patients who completed the IEDAT-04-2022 trial which studied the neurological effects of EryDex on subjects with ataxia telangiectas...
What is the current status of trial NCT06664853?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 101 participants. The study started on 2024-12-11. Estimated completion is 2026-01-30.
What interventions are being tested in trial NCT06664853?
The interventions under investigation include: Dexamethasone sodium phosphate (DRUG).
Who is sponsoring clinical trial NCT06664853?
This trial is sponsored by Quince Therapeutics S.p.A., which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06664853's enrollment target sits among peer trials
101 1680th of 2000 higher than 320 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04033497 · 101 participants · NA
Treatment Response Assessment Maps to Delineate Necrosis From Tumor After Stereotactic Radiation in Brain Metastases
- NCT05111574 · 101 participants · Phase 2
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
- NCT05984680 · 101 participants
COPD Care Pathway Among Patients With Cancer
- NCT06266299 · 101 participants · Phase 1
A Study of KK2269 in Adult Participants With Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI